HIGHLIGHTS
- who: BRCA mutation et al. from the University of Erlangen Nuremberg, Germany have published the paper: Clinical Bene fi ts of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1 -Del ex9-12, in the Journal: (JOURNAL) of 31/05/2021
- what: The aim of this study was to describe the survival rate of OC patients treated with olaparib, emphasizing patients carrying the Mexican founder mutation (BRCA1-Del ex9-12). Probably, the main reason regarding the difference in survival between patients with small-scale BRCA mutations and LGRs relies on the resistance mechanisms to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.